TNF and neoplasm: Composed of TNF fused to the L19 antibody, L19TNF is a fully human antibody–cytokine fusion designed to selectively deliver TNF to tumors by binding a fibronectin epitope uniquely expressed in the tumor extracellular matrix, where it induces cell death, and at the same time the reduction of toxicity to healthy organs (202) (Figure 3C).